Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06964191 · ClinicalTrials.gov registry record · Phase 2
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
A Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by PolyActiva Pty.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06964191 is a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle that is actively recruiting participants, run by PolyActiva Pty. The registered enrollment target is 75 participants, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06964191, a Phase 2 study of Ocular Hypertension and Glaucoma Open-Angle, is actively recruiting participants, sponsored by PolyActiva Pty.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.
Conditions Studied
Interventions
- DRUG Latanoprost 0.005% Ophthalmic Solution
- COMBINATION_PRODUCT PA5108 Ocular Implant low dose
- COMBINATION_PRODUCT PA5108 Ocular Implant, high dose
Study Locations (1)
California
- Eye Research Foundation - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-05-31 |
| Est. Completion | 2026-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06964191
The ClinicalTrials.gov registry entry for NCT06964191 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (73% lower). The listed sponsor is PolyActiva Pty, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Latanoprost 0.005% Ophthalmic Solution is the first listed.
NCT06964191 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06964191 about?
NCT06964191 is a clinical study titled "Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension". The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to the standard treatment therapy.
What is the current status of trial NCT06964191?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2025-05-31. Estimated completion is 2026-11-15.
What conditions does trial NCT06964191 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT06964191?
The interventions under investigation include: Latanoprost 0.005% Ophthalmic Solution (DRUG), PA5108 Ocular Implant low dose (COMBINATION_PRODUCT), PA5108 Ocular Implant, high dose (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06964191?
This trial is sponsored by PolyActiva Pty, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06964191 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Travoprost Five Day Posology Study
COMPLETED · Phase 2
-
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
COMPLETED · Phase 2
-
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
COMPLETED · Phase 2
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
COMPLETED · Phase 2
-
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.